Pavel V. Gavrilov
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Pavel V. Gavrilov has a total of 26 co-authors. Here are the top co-authors by number of shared publications:
- Sergey Vladimirovich Zhuravel
N.V. Sklifosovsky Research Institute for Emergency Medicine; Pirogov Russian National Research Medical University; A.I. Yevdokimov Moscow State University of Medicine and Dentistry
6 shared publications - Irina I. Utkina
N.V. Sklifosovsky Research Institute for Emergency Medicine
5 shared publications - Aleksander G. Chuchalin
Pirogov Russian National Research Medical University
3 shared publications - Anna M. Ryabokon
Russian Academy of Sciences
3 shared publications - Lyudmila V. Shogenova
Federal State Autonomous Educational Institution of Higher Education “N.I.Pirogov Russian National Research Medical University” of the Ministry of Health of the Russian Federation
3 shared publications - Sergey D. Varfolomeev
Emanuel Institute of Biochemical Physics, Russian Academy of Sciences, Moscow, Russia
3 shared publications
Latest Publications
- Open Access
- 15 January 2022
- Published by The Scientific and Practical Society of Emergency Medicine Physicians in Russian Sklifosovsky Journal "Emergency Medical Care"
- Vol. 10 (4) , 642-648-648
Antithrombin-III for New Coronavirus Infection (COVID-19) Under Conditions of Extracorporeal Membrane Oxygenation (Clinical Observation)
COVID-19 is a disease that, in addition to respiratory failure, leads to thrombosis and bleeding due to coagulation disorders. Extracorporeal membrane oxygenation (ECMO), required in cases of a deterioration of gas exchange function of the lungs, contributes to changes in blood coagulation indicators, which leads to an increased risk of hemorrhagic complications and thrombosis. In the article, a clinical case of a severe course of COVID-19 is reported, which required ECMO. During the treatment, antithrombin-III was used, which allowed avoiding life-threatening complications and successfully completing the procedure.
- 15 January 2022
- Published by The Scientific and Practical Society of Emergency Medicine Physicians in Russian Sklifosovsky Journal "Emergency Medical Care"
- Vol. 10 (4) , 642-648-648
Open AccessAntithrombin-III for New Coronavirus Infection (COVID-19) Under Conditions of Extracorporeal Membrane Oxygenation (Clinical Observation)
COVID-19 is a disease that, in addition to respiratory failure, leads to thrombosis and bleeding due to coagulation disorders. Extracorporeal membrane oxygenation (ECMO), required in cases of a deterioration of gas exchange function of the lungs, contributes to changes in blood coagulation indicators, which leads to an increased risk of hemorrhagic complications and thrombosis. In the article, a clinical case of a severe course of COVID-19 is reported, which required ECMO. During the treatment, antithrombin-III was used, which allowed avoiding life-threatening complications and successfully completing the procedure.
- Open Access
- 13 April 2021
- Published by Reaviz Medical University in Bulletin of the Medical Institute "REAVIZ" (REHABILITATION, DOCTOR AND HEALTH)
- No. 1,p. 5-10
Case report: thermal helium in the treatment of coronavirus pneumonia caused by new coronavirus infection COVID-19 (SARS-CoV-2)
The novel SARS-CoV-2 coronavirus, which originated in December 2019 in Wuhan, China, has triggered an outbreak of a respiratory illness called COVID-19. Helium is a colorless inert gas, odorless and tasteless. Thermal helium-oxygen therapy is a new and innovative method that allows you to maintain the diffusion capacity of the lungs. The clinical case presented in this article shows that inhalation of a thermal gas mixture of helium and oxygen (t-He/O2) in the standard therapy of a patient with pneumonia caused by SARS-CoV-2 positively influenced the clinical picture of the disease, improves gas exchange, and promotes accelerating the elimination of the virus, rehabilitation and discharge of the patient.
- 13 April 2021
- Published by Reaviz Medical University in Bulletin of the Medical Institute "REAVIZ" (REHABILITATION, DOCTOR AND HEALTH)
- No. 1,p. 5-10
Open AccessCase report: thermal helium in the treatment of coronavirus pneumonia caused by new coronavirus infection COVID-19 (SARS-CoV-2)
The novel SARS-CoV-2 coronavirus, which originated in December 2019 in Wuhan, China, has triggered an outbreak of a respiratory illness called COVID-19. Helium is a colorless inert gas, odorless and tasteless. Thermal helium-oxygen therapy is a new and innovative method that allows you to maintain the diffusion capacity of the lungs. The clinical case presented in this article shows that inhalation of a thermal gas mixture of helium and oxygen (t-He/O2) in the standard therapy of a patient with pneumonia caused by SARS-CoV-2 positively influenced the clinical picture of the disease, improves gas exchange, and promotes accelerating the elimination of the virus, rehabilitation and discharge of the patient.
- Open Access
- 10 March 2021
- Published by Pleiades Publishing Ltd in Doklady Biochemistry and Biophysics
- Vol. 496 (1) , 44-47
Thermovaccination: Thermoheliox as an Immune Response Stimulant. Kinetics of Antibodies and C-Reactive Protein Synthesis in Coronaviral Infection
The high efficiency of using thermoheliox (inhalation with a high-temperature mixture of helium and oxygen) in the treatment of patients affected by COVID-19 was shown. The dynamics of accumulation of IgG, IgM, and C-reactive protein (CRP) in patients with coronavirus infection in the “working” and control groups was studied experimentally. It was shown that thermoheliox intensifies the synthesis of IgG, IgM, and CRP antibodies, while eliminating the induction period on the kinetic curves of the synthesis of specific antibodies in the IgG form and transfers the synthesis of CRP to a fast phase. The results of experiments confirm the previously obtained data based on the analysis of the kinetic model of the development of coronaviral infection in the human body.
- 10 March 2021
- Published by Pleiades Publishing Ltd in Doklady Biochemistry and Biophysics
- Vol. 496 (1) , 44-47
Open AccessThermovaccination: Thermoheliox as an Immune Response Stimulant. Kinetics of Antibodies and C-Reactive Protein Synthesis in Coronaviral Infection
The high efficiency of using thermoheliox (inhalation with a high-temperature mixture of helium and oxygen) in the treatment of patients affected by COVID-19 was shown. The dynamics of accumulation of IgG, IgM, and C-reactive protein (CRP) in patients with coronavirus infection in the “working” and control groups was studied experimentally. It was shown that thermoheliox intensifies the synthesis of IgG, IgM, and CRP antibodies, while eliminating the induction period on the kinetic curves of the synthesis of specific antibodies in the IgG form and transfers the synthesis of CRP to a fast phase. The results of experiments confirm the previously obtained data based on the analysis of the kinetic model of the development of coronaviral infection in the human body.
- Open Access
- 4 December 2020
- Published by Paediatrician Publishers LLC in Annals of the Russian academy of medical sciences
- Vol. 75 (5S) , 353-362
Thermal Helium-Oxygen Mixture as Part of a Treatment Protocol for Patients with COVID-19
Background. The paper discusses the use of a thermal helium-oxygen mixture (t-Не/О2 ), a novel technology, in treating patients with the 2019-nCoV acute respiratory disease (COVID-19) who develop life-threatening respiratory failure. Aim to evaluate the safety and efficacy of t-Не/О2 inhalation combined with standard therapy in the treatment of acute respiratory failure in patients with COVID-19. Materials and Methods. This was a single-center, randomized, prospective study of 70 patients with COVID-19. All patients were divided into two groups: in Group 1 (n = 38) patients received t-He/О2 in addition to the standard COVID-19 treatment; and in Group 2 (n = 32) patients were given the standard treatment in accordance with the Clinical Treatment Guidelines for patients with COVID-19, developed by the Ministry of Health of the Russian Federation. The male/female ratio was 18/20 in Group 1 and 18/14 in Group 2. The mean age of the patients in the study was 53.5 years (43; 62): 56 years (42; 64) in Group 1 and 52 years (43; 66) in Group 2. All patients had computed tomography (CT) signs of lung injury: ground-glass opacities and areas of consolidation. SARS-CoV-2 RNA was detected in 30 Group 1 patients and 28 Group 2 patients. The patients were matched by sex, age, body mass index (BMI), area of pulmonary involvement, and laboratory findings. All patients provided voluntary informed consent to participate in the study and signed a consent form. Results. Inhalation of thermal helium-oxygen mixture combined with standard therapy did not cause any procedure-related side effects in any of the patients. The following changes were observed in all patients: pO2 /FiO2 , SpO2 , and lymphocyte counts increased, C-reactive protein (CRP) levels decreased, and D-dimer and ferritin levels returned to normal. In Group 1 statistically significant changes in the above-mentioned parameters were seen within three days, while in Group 2 the same changes were observed between Days 7 and 10 of treatment. In Group 1 patients cleared SARS-CoV-2 within 4872 hours after initiation of inhalation, which was confirmed by polymerase chain reaction (PCR), and in Group 2 virus elimination was achieved within 72168 hours. Conclusion. The addition of inhalation of a thermal gas mixture of helium and oxygen (t-He/О2 ) to the standard therapy for patients with SARS-CoV-2 infection, CT signs of pneumonia (grades СT2 or CT3), and acute respiratory failure improves gas exchange, contributes to a more rapid virus elimination, and indirectly reduces inflammation.
- 4 December 2020
- Published by Paediatrician Publishers LLC in Annals of the Russian academy of medical sciences
- Vol. 75 (5S) , 353-362
Open AccessThermal Helium-Oxygen Mixture as Part of a Treatment Protocol for Patients with COVID-19
Background. The paper discusses the use of a thermal helium-oxygen mixture (t-Не/О2 ), a novel technology, in treating patients with the 2019-nCoV acute respiratory disease (COVID-19) who develop life-threatening respiratory failure. Aim to evaluate the safety and efficacy of t-Не/О2 inhalation combined with standard therapy in the treatment of acute respiratory failure in patients with COVID-19. Materials and Methods. This was a single-center, randomized, prospective study of 70 patients with COVID-19. All patients were divided into two groups: in Group 1 (n = 38) patients received t-He/О2 in addition to the standard COVID-19 treatment; and in Group 2 (n = 32) patients were given the standard treatment in accordance with the Clinical Treatment Guidelines for patients with COVID-19, developed by the Ministry of Health of the Russian Federation. The male/female ratio was 18/20 in Group 1 and 18/14 in Group 2. The mean age of the patients in the study was 53.5 years (43; 62): 56 years (42; 64) in Group 1 and 52 years (43; 66) in Group 2. All patients had computed tomography (CT) signs of lung injury: ground-glass opacities and areas of consolidation. SARS-CoV-2 RNA was detected in 30 Group 1 patients and 28 Group 2 patients. The patients were matched by sex, age, body mass index (BMI), area of pulmonary involvement, and laboratory findings. All patients provided voluntary informed consent to participate in the study and signed a consent form. Results. Inhalation of thermal helium-oxygen mixture combined with standard therapy did not cause any procedure-related side effects in any of the patients. The following changes were observed in all patients: pO2 /FiO2 , SpO2 , and lymphocyte counts increased, C-reactive protein (CRP) levels decreased, and D-dimer and ferritin levels returned to normal. In Group 1 statistically significant changes in the above-mentioned parameters were seen within three days, while in Group 2 the same changes were observed between Days 7 and 10 of treatment. In Group 1 patients cleared SARS-CoV-2 within 4872 hours after initiation of inhalation, which was confirmed by polymerase chain reaction (PCR), and in Group 2 virus elimination was achieved within 72168 hours. Conclusion. The addition of inhalation of a thermal gas mixture of helium and oxygen (t-He/О2 ) to the standard therapy for patients with SARS-CoV-2 infection, CT signs of pneumonia (grades СT2 or CT3), and acute respiratory failure improves gas exchange, contributes to a more rapid virus elimination, and indirectly reduces inflammation.
- Open Access
- 26 October 2020
- Published by Scientific and Practical Reviewed Journal Pulmonology in PULMONOLOGIYA
- Vol. 30 (5) , 533-543
Effect of thermal helium-oxygen mixture on viral load in COVID-19
Влияние термической гелий-кислородной смеси на вирусную нагрузку при COVID-19
- 26 October 2020
- Published by Scientific and Practical Reviewed Journal Pulmonology in PULMONOLOGIYA
- Vol. 30 (5) , 533-543
Open AccessEffect of thermal helium-oxygen mixture on viral load in COVID-19
Влияние термической гелий-кислородной смеси на вирусную нагрузку при COVID-19
- Open Access
- 18 June 2020
- Published by IPO Association of Transplantologists in Transplantologiya. The Russian Journal of Transplantation
- Vol. 12 (2) , 104-111
Comparing the results of invasive candidiasis prevention with anidulafungin vs. the lipid formulation of amphotericin B in high-risk patients in the early postoperative period after liver transplantation
Introduction. The development of invasive candidiasis leads to high mortality after liver transplantation. Choosing an effective prophylaxis is an important task.The study purpose was to compare the results of invasive candidiasis prevention with anidulafungin vs. the lipid formulation of amphotericin B in high-risk patients in the early postoperative period after liver transplantation. Material and methods. The study included 80 patients with risk factors for the development of invasive mycosis who underwent liver transplantation. Patients were divided into 2 groups. In the first group (n = 40), anidulafungin was prescribed for prophylaxis; in the 2nd group (n = 40), the lipid complex of amphotericin B was used.Results. The most common of Candida spp. isolated in the patients of our study, as expected, was Candida albicans accounting for 31.2%, significantly less than a half. Neither fungal infection breakthrough nor invasive mycosis development were reported in any patient. In group 2, renal replacement therapy was significantly more frequently used. In two cases, the amphotericin B lipid complex was canceled and the conversion to echinocandin was undertaken due to the occurrence of adverse events (chills and fever) associated, in our opinion, with the drug used. Conclusions. 1. Patients after liver transplantation with 2 or more risk factors have absolute indications to invasive mycosis prevention. 2. Anidulafungin and the lipid formulation of amphotericin B are effective for prophylaxis and prevention of fungal infection breakthrough. 3. Anidulafungin has an advantage in safety over the lipid formulation of amphotericin B.
- 18 June 2020
- Published by IPO Association of Transplantologists in Transplantologiya. The Russian Journal of Transplantation
- Vol. 12 (2) , 104-111
Open AccessComparing the results of invasive candidiasis prevention with anidulafungin vs. the lipid formulation of amphotericin B in high-risk patients in the early postoperative period after liver transplantation
Introduction. The development of invasive candidiasis leads to high mortality after liver transplantation. Choosing an effective prophylaxis is an important task.The study purpose was to compare the results of invasive candidiasis prevention with anidulafungin vs. the lipid formulation of amphotericin B in high-risk patients in the early postoperative period after liver transplantation. Material and methods. The study included 80 patients with risk factors for the development of invasive mycosis who underwent liver transplantation. Patients were divided into 2 groups. In the first group (n = 40), anidulafungin was prescribed for prophylaxis; in the 2nd group (n = 40), the lipid complex of amphotericin B was used.Results. The most common of Candida spp. isolated in the patients of our study, as expected, was Candida albicans accounting for 31.2%, significantly less than a half. Neither fungal infection breakthrough nor invasive mycosis development were reported in any patient. In group 2, renal replacement therapy was significantly more frequently used. In two cases, the amphotericin B lipid complex was canceled and the conversion to echinocandin was undertaken due to the occurrence of adverse events (chills and fever) associated, in our opinion, with the drug used. Conclusions. 1. Patients after liver transplantation with 2 or more risk factors have absolute indications to invasive mycosis prevention. 2. Anidulafungin and the lipid formulation of amphotericin B are effective for prophylaxis and prevention of fungal infection breakthrough. 3. Anidulafungin has an advantage in safety over the lipid formulation of amphotericin B.
- 1 April 2015
- Published by Elsevier in European Urology Supplements
- Vol. 14 (2) , e502
502 QoL in women with bladder exstrophy
- 1 April 2015
- Published by Elsevier in European Urology Supplements
- Vol. 14 (2) , e502
502 QoL in women with bladder exstrophy